Ascierto, Paolo Antonio http://orcid.org/0000-0002-8322-475X
Ferrucci, Pier Francesco
Fisher, Rosalie
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Di Giacomo, Anna Maria
Svane, Inge Marie
Lotem, Michal
Bar-Sela, Gil
Couture, Felix
Mookerjee, Bijoyesh
Ghori, Razi
Ibrahim, Nageatte
Moreno, Blanca Homet
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Article History
Received: 18 January 2019
Accepted: 8 April 2019
First Online: 6 June 2019
Competing interests
: P.A.A. reports receiving research funds and fees for serving on advisory boards of Bristol-Myers Squibb, Roche-Genentech and Array Biopharma and fees for serving on advisory boards of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Amgen, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, MedImmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera and Ultimovacs. P.F.F. reports receiving fees for serving on advisory boards of Bristol-Myers Squibb, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Pierre Fabre and Roche. R.F. reports receiving a honorarium for speaking engagement from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. M.D.V. reports receiving fees for serving on advisory boards of Bristol-Myers Squibb, Novartis and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. V.A. reports receiving fees for serving on advisory boards, speaker fees, travel support from Bristol-Myers Squibb, speaker fees and fees for serving on advisory boards of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Merck Serono and Novartis and fees for serving on advisory boards of Pierre Fabre. H.S. reports receiving research funds from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, personal fees and non-financial support from Bristol-Myers Squibb and personal fees from Roche, Incyte and Novartis. J.S. reports no competing interests. P.Q. reports receiving fees for serving on advisory boards of Roche, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Bristol-Myers Squibb and Novartis. G.V.L. reports receiving fees for serving on advisory boards of Aduro, Amgen, Array Biopharma, Bristol-Myers Squibb, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Oncosec and Pierre Fabre. A.M.D.G. reports receiving personal fees for educational activities for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and fees for serving on advisory boards of Bristol-Myers Squibb, Incyte and Pierre Fabre. I.M.S. reports receiving honoraria for teaching and serving on advisory board of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, fees for serving on advisory board and non-financial support for conference participation from Novartis. M.L. reports receiving consulting fees from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Bristol-Myers Squibb. G.B.-S. reports receiving grants from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. F.C. reports no competing interests. B.M. reports stock options and employment at Novartis and stocks at GlaxoSmithKline and AstraZeneca. R.G. reports employment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. N.I. reports stock ownership at GlaxoSmithKline and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. B.H.M. reports employment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. A.R. reports receiving honoraria for consulting at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Amgen, Bristol-Myers Squibb, Chugai, Genentech and Roche and participation in scientific advisory board and stock ownership in Advaxis, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Kite-Gilead, Merus, Rgenix, Lutris, PACT Pharma and Tango Therapeutics.